GlassScriptPhysician profile
John H Feibel
NPI 1033227780
$1,369.13
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $167 · 2021: $47.78 · 2022: $97.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $234.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $125.56 | 2019-2020 | |
| Genzyme Corporation | $121.47 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $105.80 | 2019 | |
| Amneal Pharmaceuticals LLC | $102.10 | 2021-2022 | |
| Ucb, INC. | $96.63 | 2019 | |
| Emd Serono, INC. | $56.23 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $49.75 | 2019 | |
| Lundbeck LLC | $47.83 | 2019 | |
| Ge Healthcare | $47.22 | 2019-2020 | |
| Eisai INC. | $35.10 | 2019 | |
| Zimvie INC. | $25.89 | 2022 | |
| Allergan, INC. | $25.83 | 2019-2020 | |
| Akcea Therapeutics, INC. | $23.42 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $23.10 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $19.97 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.50 | 2019 | |
| Amgen INC. | $18.77 | 2019 | |
| Abbvie INC. | $18.63 | 2019 | |
| Neurelis, INC. | $17.20 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.41 | 2019 | |
| Grifols USA, LLC | $16.12 | 2020 | |
| Tanabe Pharma America, INC. | $16.08 | 2019 | |
| Acadia Pharmaceuticals INC | $15.16 | 2019 | |
| Assertio Therapeutics, INC. | $15.07 | 2019 | |
| Aquestive Therapeutics, INC. | $14.66 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.10 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.99 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $11.90 | 2020 | |
| Neurocrine Biosciences, INC. | $11.14 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Feibel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.